<div id="readability-page-1"><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>An update from TransThera Sciences (Nanjing). Inc. ( (HK:2617) ) is now available. TransThera Sciences (Nanjing), Inc. has launched a placement of 3,836,000 new H shares at HK$40.83 each, representing about 1.24% of its existing H-share capital, under its existing general mandate. The shares, to be allocated to at least six institutional and professional investors at an 18% discount to recent market prices, will modestly dilute existing holders while broadening the shareholder base. The placement is expected to raise gross proceeds of roughly HK$156.62 million and net proceeds of about HK$152.13 million, with a net issue price of approximately HK$39.66 per share. As the deal is on a best-effort basis and subject to conditions and regulatory approvals, the transaction may not complete, leaving investors alert to execution risk as the company seeks fresh capital for its ongoing operations and strategic plans. More about TransThera Sciences (Nanjing). Inc. TransThera Sciences (Nanjing), Inc. is a joint stock company incorporated in the People’s Republic of China and listed in Hong Kong under stock code 2617. The company operates in the biopharmaceutical sector and accesses international capital markets through H-share issuances to support its research, development and commercialization activities. Average Trading Volume: 2,500,535 Technical Sentiment Signal: Strong Sell Current Market Cap: HK$15B Find detailed analytics on 2617 stock on TipRanks’ Stock Analysis page.</div>

516930

159992

159849

TransThera Sciences (Nanjing), Inc. is raising HK$156 million through a placement of 3,836,000 new H shares at HK$40.83 each, an 18% discount to market prices. This represents 1.24% of its existing H-share capital and aims to broaden the shareholder base despite modest dilution for current holders. The transaction is subject to regulatory approvals and may not complete, posing execution risks as the company seeks capital for operations and strategic plans.

Tip Ranks

Minsheng Royal CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

China Merchants CSI Biotechnology Theme ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC SSE STAR Biology and Medicine ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

ChinaAMC CSI Biotechnology Theme ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Guotai CSI Bio-medicine ETF

Penghua CSI HK Connect Health Care Composite ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Fullgoal CSI Hugangshen Innovative Drugs Industry ETF

E Fund CSI Biotechnology Theme ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

TRANSTHERA-B

TransThera Sciences to Raise HK$156 Million via Discounted H-Share Placement